Ser367
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.4
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser367  -  ATM (human)

Site Information
DTRSLEIsQSyTttQ   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 467198
Available spectra:  1 CST

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 2 , 3 , 5 , 6 , 7 , 8 , 9 , 10 , 11 ) , phospho-antibody ( 6 ) , western blotting ( 6 )
Disease tissue studied:
ataxia-telangiectasia ( 6 ) , ataxia-telangiectasic cancer ( 11 ) , brain cancer ( 9 ) , glioblastoma ( 9 ) , glioma ( 9 ) , lung cancer ( 3 ) , non-small cell lung cancer ( 3 ) , non-small cell lung adenocarcinoma ( 3 ) , non-small cell large cell lung carcinoma ( 3 ) , Nijmegen Breakage Syndrome ( 11 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Putative in vivo kinases:
ATM (human) ( 6 )
Kinases, in vitro:
ATM (human) ( 6 , 11 )
Treatments:
ionizing_radiation ( 1 , 6 , 8 ) , KU-55933 ( 6 ) , UV ( 9 ) , wortmannin ( 6 )

Downstream Regulation
Effects of modification on ATM:
enzymatic activity, induced ( 6 )

References 

1

Lee HJ, et al. (2015) Tyrosine 370 phosphorylation of ATM positively regulates DNA damage response. Cell Res 25, 225-36
25601159   Curated Info

2

Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94
25159151   Curated Info

3

Rikova K, Hall B (2013) CST Curation Set: 20737, 21164, 30161, 30162, 30163; Year: 2013; Biosample/Treatment: cell line, H1299, H1944, H358, H1734, H460; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

4

Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25
22424773   Curated Info

5

Zhou J (2011) CST Curation Set: 11710; Year: 2011; Biosample/Treatment: cell line, HeLa/UV; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho-ATM/ATR Substrate (S*Q) (D23H2/D69H5) Rabbit mAb Cat#: 9607, PTMScan(R) Phospho-ATM/ATR Substrate (S*Q) Immunoaffinity Beads Cat#: 9884
Curated Info

6

Kozlov SV, et al. (2011) Autophosphorylation and ATM activation: additional sites add to the complexity. J Biol Chem 286, 9107-19
21149446   Curated Info

7

Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5
21712546   Curated Info

8

Bennetzen MV, et al. (2010) Site-specific phosphorylation dynamics of the nuclear proteome during the DNA damage response. Mol Cell Proteomics 9, 1314-23
20164059   Curated Info

9

Stokes MP, et al. (2007) Profiling of UV-induced ATM/ATR signaling pathways. Proc Natl Acad Sci U S A 104, 19855-60
18077418   Curated Info

10

Matsuoka S, et al. (2007) ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science 316, 1160-6
17525332   Curated Info

11

Kozlov SV, et al. (2006) Involvement of novel autophosphorylation sites in ATM activation. EMBO J 25, 3504-14
16858402   Curated Info